Germline genetic testing for BRCA1 and BRCA2 (BRCA) has enabled risk management for individuals at elevated cancer risk, and with the advent of PARP inhibitor treatment, enabled treatment selection with improved outcomes.1 In high resource countries, clinical genetics services are well established and patients are referred for germline BRCA genetic testing using criteria based on age of onset of cancer, breast cancer histology, and cancer family history.2,3. The gene discussed is BRCA2; the disease is breast carcinoma.